Rational engineering of Escherichia coli strains for plasmid biopharmaceutical manufacturing
Plasmid DNA (pDNA) has become very attractive as a biopharmaceutical, especially for gene therapy and DNA vaccination. Currently, there are a few products licensed for veterinary applications and numerous plasmids in clinical trials for use in humans. Recent work in both academia and industry demons...
Main Authors: | Gonçalves, Geisa A. L. (Author), Bower, Diana Morgan (Author), Prazeres, Duarte M. F. (Author), Monteiro, Gabriel A. (Author), Jones, Kristala L. (Author) |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor) |
Format: | Article |
Language: | English |
Published: |
Wiley,
2019-07-18T18:36:10Z.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
Engineering of Escherichia coli strains for plasmid biopharmaceutical production: Scale-up challenges
by: Monteiro, Gabriel A., et al.
Published: (2016) -
De novo creation of MG1655-derived E. coli strains specifically designed for plasmid DNA production
by: Gonçalves, Geisa A. L., et al.
Published: (2013) -
Engineering of bacterial strains and vectors for the production of plasmid DNA
by: Prather, Kristala L. Jones, et al.
Published: (2009) -
Development of new tools for the production of plasmid DNA biopharmaceuticals
by: Bower, Diana M. (Diana Morgan)
Published: (2013) -
Development of new plasmid DNA vaccine vectors with R1-based replicons
by: Bower, Diana Morgan, et al.
Published: (2012)